Related Experiment Video
Updated: Feb 17, 2026

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
Published on: May 10, 2022
Post-transfusion changes in serum hepcidin and iron parameters in preterm infants
Fotini Stripeli1, John Kapetanakis1, Dimitris Gourgiotis2
1Neonatal Intensive Care Unit, P&A Kyriakou Children's Hospital, Athens, Greece.
Insights
Serum hepcidin levels increase after packed red blood cell transfusions in preterm infants. These changes, along with immature reticulocyte fraction (IRF) and high-light-scatter reticulocytes (HLR), may help assess iron status in neonates.
Area of Science:
- Neonatal Medicine
- Hematology
- Pediatric Iron Metabolism
Background:
- Packed red blood cell transfusions are a common intervention for preterm neonates.
- Hepcidin regulates iron levels, but its role in transfused preterm infants is not well understood.
- Immature reticulocyte fraction (IRF) and high-light-scatter reticulocytes (HLR) are key indicators of iron metabolism.
Purpose of the Study:
- To evaluate serum hepcidin concentrations in preterm infants following transfusion.
- To establish hematological parameters related to iron metabolism post-transfusion.
- To explore the relationship between hepcidin and iron status indicators in this population.
Main Methods:
- Blood samples were collected from 19 preterm neonates (mean gestational age 29.1 weeks) before and at 5 days and 1 month after transfusion.
- Serum hepcidin levels were measured.
- Iron parameters including IRF and HLR were assessed.
Main Results:
- Serum hepcidin significantly increased 5 days post-transfusion (5.5 vs 10 ng/mL, P = 0.005).
- IRF and % HLR significantly decreased 5 days post-transfusion (P = 0.009 and P = 0.012, respectively).
- Changes in hepcidin correlated with mean corpuscular hemoglobin, total iron binding capacity, and transferrin levels.
Conclusions:
- Serum hepcidin, IRF, and HLR show potential for assessing iron status before and after transfusion in preterm infants.
- Further research with larger cohorts is recommended to determine the sensitivity and specificity of hepcidin compared to standard iron parameters.
Background:
Packed red blood cell transfusion is common in preterm neonates. Hepcidin acts as a negative feedback iron regulator. Iron parameters such as immature reticulocyte fraction (IRF) and high-light-scatter reticulocytes (HLR) are used to clarify iron metabolism. Very little is known about the regulation of hepcidin in preterm infants because most reports have evaluated prohepcidin. The aim of this study was therefore to evaluate serum hepcidin and establish hematological parameters in preterm infants after transfusion.
Methods:
The subjects consisted of 19 newborns (10 boys) with mean gestational age 29.1 ± 2.0 weeks, who had been transfused at the chronological age of 44.84 ± 19.61 days. Blood sample was collected before the transfusion and thereafter at 5 days and at 1 month. Serum hepcidin and other iron parameters were evaluated.
Results:
Mean serum hepcidin before and 5 days after transfusion was significantly different (5.5 ± 5.1 vs 10 ± 7.9 ng/mL respectively, P = 0.005). IRF and % HLR were also decreased significantly, 5 days after transfusion (0.4 ± 0.2 vs 0.2 ± 0.1, P = 0.009; 1.4 ± 1.5% vs 0.5 ± 0.4%, P = 0.012, respectively). Changes in hepcidin 5 days after transfusion were correlated significantly with changes in mean corpuscular hemoglobin (β, 0.13; SE, 0.05; P = 0.017), total iron binding capacity (β, 3.74; SE, 1.56; P = 0.016) and transferrin (β, 2.9, SE, 1.4; P = 0.039).
Conclusions:
Serum hepcidin concentration, along with IRF and HLR, are potentially useful in estimating pre- and post-transfusion iron status. Larger studies are needed to evaluate the sensitivity and specificity of hepcidin compared with ordinary iron parameters in premature infants.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
The Early Endosome: Endocytosis of Transferrin
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Pharmacokinetics in Pediatric Patients: Drug Metabolism

